Ubs Group Ag Aadi Bioscience, Inc. Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
A detailed history of Ubs Group Ag transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 70,365 shares of AADI stock, worth $135,804. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,365
Previous 20,711
239.75%
Holding current value
$135,804
Previous $48,000
112.5%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AADI
# of Institutions
68Shares Held
12MCall Options Held
9.4KPut Options Held
2.5K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.5 Million0.06% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.57 Million2.91% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.15 Million4.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.48 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC526KShares$1.02 Million1.41% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $40.6M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...